IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma

British Journal of Cancer

Volumn 115, Issue 10, 2016, Pages 1234-1244

  Matsuoka, Yuichiro ^a   Nakayama, Hideki ^a   Yoshida, Ryoji ^a   Hirosue, Akiyuki ^a   Nagata, Masashi ^a   Tanaka, Takuya ^a   Kawahara, Kenta ^a   Sakata, Junki ^a   Arita, Hidetaka ^a   Nakashima, Hikaru ^a   Shinriki, Satoru ^b,c   Fukuma, Daiki ^a   Ogi, Hidenao ^a   Hiraki, Akimitsu ^d   Shinohara, Masanori ^a   Toya, Ryo ^c   Murakami, Ryuji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^d FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

Interleukin 6 (IL 6); nuclear factor erythroid 2 related factor 2 (Nrf2); oral squamous cell carcinoma (OSCC); radiation; reactive oxygen species (ROS); resistance

Indexed keywords

CD163 ANTIGEN; HISTONE H2AX; INTERLEUKIN 6; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TOCILIZUMAB; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; IL6 PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; NFE2L2 PROTEIN, HUMAN;

ARTICLE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION ASSAY; CLONOGENIC ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MOUTH SQUAMOUS CELL CARCINOMA; OXIDATIVE STRESS; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING; X IRRADIATION; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; METABOLISM; MOUTH NEOPLASMS; PHYSIOLOGY; PROCEDURES; RADIATION TOLERANCE; TUMOR CELL LINE; X RAY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA DAMAGE; HUMANS; INTERLEUKIN-6; MOUTH NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RADIATION TOLERANCE; RADIOTHERAPY; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; X-RAYS;

EID: 84991030307     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.327     Document Type: Article

References (37)

1. Bochet L, Meulle A, Imbert S, Salles B, Valet P, Muller C (2011) Cancerassociated adipocytes promotes breast tumour radioresistance. Biochem Biophys Res Commun 411(1): 102-106.
2. Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD, Chen MF (2010) Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 76(4): 1214-1224.
3. Chen MF, Hsieh CC, Chen WC, Lai CH (2012) Role of interleukin-6 in the radiation response of liver tumours. Int J Radiat Oncol Biol Phys 84(5): e621-e630.
4. Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, Wang X, Keng P, Lee SO (2015) IL-6 signaling promotes DNA repair and prevents apoptosis in CD133\+ stem-like cells of lung cancer after radiation. Radiat Oncol 10: 227.
5. Deorukhkar A, Krishnan S (2010) Targeting inflammatory pathways for tumour radiosensitization. Biochem Pharmacol 80(12): 1904-1914.
6. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, LamJS, Ailles LE, WongM, Joshua B, KaplanMJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239): 780-783.
7. Dubost JJ, Rolhion C, Tchirkov A, Bertrand S, Chassagne J, Dosgilbert A, Verrelle P (2002) Interleukin-6-producing cells in a human glioblastoma cell line are not affected by ionizing radiation. J Neuro-oncol 56(1): 29-34.
8. Fisher CJ, Goswami PC (2008) Mitochondria-targeted antioxidant enzyme activity regulates radioresistance in human pancreatic cancer cells. Cancer Biol Ther 7(8): 1271-1279.
9. Fisher DT, Appenheimer MM, Evans SS (2014) The two faces of IL-6 in the tumour microenvironment. Semin Immunol 26(1): 38-47.
10. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7): 904-910.
11. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41(16): 2502-2512.
12. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M (2013) Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 51(5): 618-631.
13. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1.Nat Cell Biol 12(3): 213-223.
14. Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumours. Cancer Sci 105(1): 1-8.
15. Kuwahara Y, Li L, Baba T, Nakagawa H, Shimura T, Yamamoto Y, Ohkubo Y, Fukumoto M (2009) Clinically relevant radioresistant cells efficiently repair DNA double-strand breaks induced by X-rays. Cancer Sci 100(4): 747-752.
16. Kuwahara Y, Mori M, Oikawa T, Shimura T, Ohtake Y, Mori S, Ohkubo Y, Fukumoto M (2010) The modified high-density survival assay is the useful tool to predict the effectiveness of fractionated radiation exposure. J Radiat Res 51(3): 297-302.
17. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008) Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy J Natl Cancer Inst 100(11): 773-783.
18. Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, Ahn J, Song JY (2012) An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 53(4): 807-816.
19. Liu X, Sun C, Liu B, Jin X, Li P, Zheng X, Zhao T, Li F, Li Q (2016) Genistein mediates the selective radiosensitizing effect in NSCLC A549 cells via inhibiting methylation of the keap1 gene promoter region. Oncotarget 7(19): 27267-27279.
20. Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK, Weinstein IB (2010) Stat3 orchestrates tumour development and progression: the Achilles' heel of head and neck cancers Curr Cancer Drug Targets 10(1): 117-126.
21. Matsuoka Y, Yoshida R, Nakayama H, Nagata M, Hirosue A, Tanaka T, Kawahara K, Nakagawa Y, Sakata J, Arita H, Hiraki A, Shinohara M (2015) The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma. APMIS 123(3): 205-214.
22. McDonald JT, Kim K, Norris AJ, Vlashi E, Phillips TM, Lagadec C, Della Donna L, Ratikan J, Szelag H, Hlatky L, McBride WH (2010) Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res 70(21): 8886-8895.
23. Multhoff G, Radons J (2012) Radiation, inflammation, and immune responses in cancer. Front Oncol 2: 58.
24. NaHK, KimEH, Jung JH, LeeHH, Hyun JW, Surh YJ (2008) (-)-Epigallocatechin gallate induces Nrf2-mediated antioxidant enzyme expression via activation of PI3K and ERK in human mammary epithelial cells. Arch Biochem Biophys 476(2): 171-177.
25. Nagata M, Nakayama H, Tanaka T, Yoshida R, Yoshitake Y, Fukuma D, Kawahara K, Nakagawa Y, Ota K, Hiraki A, Shinohara M (2011) Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma. Br J Cancer 105(9): 1322-1330.
26. Nakashima H, Matsuoka Y, Yoshida R, Nagata M, Hirosue A, Kawahara K, Sakata J, Arita H, Hiraki A, Nakayama H (2016) Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study. BMC Cancer 16(1): 41.
27. Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, Oike Y, Endo M, Ibusuki M, Hiraki A, Nakayama H, Yoshitake Y, Shinohara M, Ando Y (2009) Humanized anti-interleukin-6 receptor antibody suppresses tumour angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 15(17): 5426-5434.
28. Shinriki S, Jono H, Ueda M, Ota K, Ota T, Sueyoshi T, Oike Y, Ibusuki M, Hiraki A, Nakayama H, Shinohara M, Ando Y (2011) Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol 225(1): 142-150.
29. Taguchi K, Motohashi H, Yamamoto M (2011) Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16(2): 123-140.
30. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, Weichselbaum RR (2004) Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 279(3): 2273-2280.
31. Wu CT, Chen MF, Chen WC, Hsieh CC (2013) The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol 8: 159.
32. Yoshida R, Nakayama H, Nagata M, Hirosue A, Tanaka T, Kawahara K, Nakagawa Y, Matsuoka Y, Sakata J, Arita H, Hiraki A, Shinohara M, Ito T (2014) Overexpression of nucleostemin contributes to an advanced malignant phenotype and a poor prognosis in oral squamous cell carcinoma. Br J Cancer 111(12): 2308-2315.
33. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1): 41-51.
34. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S (2010) Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumour growth. Mol Cancer Ther 9(2): 336-346.
35. Zhang Y, Martin SG (2014) Redox proteins and radiotherapy. Clin Oncol (R Coll Radiol) 26(5): 289-300.
36. Zhao Q, Mao A, Yan J, Sun C, Di C, Zhou X, Li H, Guo R, Zhang H (2016) Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells. Int J Oncol 48(2): 765-773.
37. Zhou S, Ye W, Shao Q, Zhang M, Liang J (2013) Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit Rev Oncol Hematol 88(3): 706-715.